---
title: "2nd line of metastatic disease-of-bladder cancer"
slug: "nd-line-of-metastatic-disease-of-bladder-cancer"
date: "2023-11-26"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[management of metastatic disease-of-bladder cancer]]

# 2nd line of metastatic disease-of-bladder cancer

- FDA-approved agents include pembrolizumab a/w â†‘ OS vs. chemo (NEJM 2017;376:1015), nivolumab a/w 24% RR (Lancet Onc 2016;17:1590), avelumab a/w 17% RR (Lancet Onc 2018;19:51). If FGFR2/3 genetic alterations, erdafitinib can be used post platinum, a/w 40% RR (NEJM 2019;381:338), but usually deferred until 3rd or 4th line
